{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T07:46:34Z","timestamp":1789631194590,"version":"build-2803163510"},"reference-count":39,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2014,2,1]],"date-time":"2014-02-01T00:00:00Z","timestamp":1391212800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,2,1]],"date-time":"2014-02-01T00:00:00Z","timestamp":1391212800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2015,2,1]],"date-time":"2015-02-01T00:00:00Z","timestamp":1422748800000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Archives of Cardiovascular Diseases"],"published-print":{"date-parts":[[2014,2]]},"DOI":"10.1016\/j.acvd.2014.01.001","type":"journal-article","created":{"date-parts":[[2014,2,18]],"date-time":"2014-02-18T00:00:21Z","timestamp":1392681621000},"page":"77-87","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":79,"title":["Use of antithrombotics in atrial fibrillation in Africa, Europe, Asia and South America: Insights from the International RealiseAF Survey"],"prefix":"10.1016","volume":"107","author":[{"given":"Habib","family":"Gamra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Murin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chern-En","family":"Chiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Naditch-Br\u00fbl\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandrine","family":"Brette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe Gabriel","family":"Steg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.acvd.2014.01.001_bib0005","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1001\/jama.285.18.2370","article-title":"Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study","volume":"285","author":"Go","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.acvd.2014.01.001_bib0010","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1136\/heart.86.5.516","article-title":"Population prevalence, incidence, and predictors of atrial fibrillation in the Renfrew\/Paisley study","volume":"86","author":"Stewart","year":"2001","journal-title":"Heart"},{"key":"10.1016\/j.acvd.2014.01.001_bib0015","doi-asserted-by":"crossref","first-page":"e257","DOI":"10.1161\/circ.114.4.257","volume":"114","author":"Fuster","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.acvd.2014.01.001_bib0020","doi-asserted-by":"crossref","first-page":"2685","DOI":"10.1001\/jama.290.20.2685","article-title":"Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice?","volume":"290","author":"Go","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.acvd.2014.01.001_bib0025","first-page":"74","article-title":"Canadian Cardiovascular Society atrial fibrillation guidelines 2010: prevention of stroke and systemic thromboembolism in atrial fibrillation and flutter","volume":"27","author":"Cairns","year":"2011","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.acvd.2014.01.001_bib0030","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1093\/eurheartj\/ehq278","article-title":"Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC)","volume":"31","author":"Camm","year":"2010","journal-title":"Eur Heart J"},{"key":"10.1016\/j.acvd.2014.01.001_bib0035","doi-asserted-by":"crossref","first-page":"546S","DOI":"10.1378\/chest.08-0678","article-title":"Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)","volume":"133","author":"Singer","year":"2008","journal-title":"Chest"},{"key":"10.1016\/j.acvd.2014.01.001_bib0040","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.jacc.2010.10.001","article-title":"2011 ACCF\/AHA\/HRS focused update on the management of patients with atrial fibrillation (Updating the 2006 Guideline): a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines","volume":"57","author":"Wann","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.acvd.2014.01.001_bib0045","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1136\/heartjnl-2011-300550","article-title":"Symptoms, functional status and quality of life in patients with controlled and uncontrolled atrial fibrillation: data from the RealiseAF cross-sectional international registry","volume":"98","author":"Steg","year":"2012","journal-title":"Heart"},{"key":"10.1016\/j.acvd.2014.01.001_bib0050","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s11239-006-9022-7","article-title":"Descriptive analysis of the process and quality of oral anticoagulation management in real-life practice in patients with chronic non-valvular atrial fibrillation: the international study of anticoagulation management (ISAM)","volume":"23","author":"Ansell","year":"2007","journal-title":"J Thromb Thrombolysis"},{"key":"10.1016\/j.acvd.2014.01.001_bib0055","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1111\/j.1532-5415.2006.00828.x","article-title":"Age and the risk of warfarin-associated hemorrhage: the anticoagulation and risk factors in atrial fibrillation study","volume":"54","author":"Fang","year":"2006","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.acvd.2014.01.001_bib0060","doi-asserted-by":"crossref","first-page":"927","DOI":"10.7326\/0003-4819-131-12-199912210-00004","article-title":"Warfarin use among ambulatory patients with nonvalvular atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study","volume":"131","author":"Go","year":"1999","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.acvd.2014.01.001_bib0065","doi-asserted-by":"crossref","first-page":"2422","DOI":"10.1093\/eurheartj\/ehi505","article-title":"Atrial fibrillation management: a prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation","volume":"26","author":"Nieuwlaat","year":"2005","journal-title":"Eur Heart J"},{"key":"10.1016\/j.acvd.2014.01.001_bib0070","doi-asserted-by":"crossref","first-page":"3018","DOI":"10.1093\/eurheartj\/ehl015","article-title":"Antithrombotic treatment in real-life atrial fibrillation patients: a report from the Euro Heart Survey on Atrial Fibrillation","volume":"27","author":"Nieuwlaat","year":"2006","journal-title":"Eur Heart J"},{"key":"10.1016\/j.acvd.2014.01.001_bib0075","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1472-6904-4-1","article-title":"Occurrence and quality of anticoagulant treatment of chronic atrial fibrillation in primary health care in Sweden: a retrospective study on electronic patient records","volume":"4","author":"Nilsson","year":"2004","journal-title":"BMC Clin Pharmacol"},{"key":"10.1016\/j.acvd.2014.01.001_bib0080","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ahj.2011.09.011","article-title":"International longitudinal registry of patients with atrial fibrillation at risk of stroke: Global Anticoagulant Registry in the FIELD (GARFIELD)","volume":"163","author":"Kakkar","year":"2012","journal-title":"Am Heart J"},{"key":"10.1016\/j.acvd.2014.01.001_bib0085","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.amjmed.2009.11.015","article-title":"Are atrial fibrillation patients receiving warfarin in accordance with stroke risk?","volume":"123","author":"Zimetbaum","year":"2010","journal-title":"Am J Med"},{"key":"10.1016\/j.acvd.2014.01.001_bib0090","first-page":"J12","article-title":"Challenges to best practice: why are guidelines not implemented?","volume":"1","author":"Faergeman","year":"1999","journal-title":"Eur Heart J"},{"key":"10.1016\/j.acvd.2014.01.001_bib0095","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1161\/STROKEAHA.107.495036","article-title":"Barriers to the use of anticoagulation for nonvalvular atrial fibrillation: a representative survey of Australian family physicians","volume":"39","author":"Gattellari","year":"2008","journal-title":"Stroke"},{"key":"10.1016\/j.acvd.2014.01.001_bib0100","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1161\/STROKEAHA.107.501825","article-title":"Comparison of 12 risk stratification schemes to predict stroke in patients with nonvalvular atrial fibrillation","volume":"39","year":"2008","journal-title":"Stroke"},{"key":"10.1016\/j.acvd.2014.01.001_bib0105","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.amjmed.2009.11.025","article-title":"Underuse of oral anticoagulants in atrial fibrillation: a systematic review","volume":"123","author":"Ogilvie","year":"2010","journal-title":"Am J Med"},{"key":"10.1016\/j.acvd.2014.01.001_bib0110","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1136\/hrt.75.2.200","article-title":"Physician variation in the management of patients with atrial fibrillation","volume":"75","author":"Lip","year":"1996","journal-title":"Heart"},{"key":"10.1016\/j.acvd.2014.01.001_bib0115","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/j.ahj.2012.02.008","article-title":"International variation in use of oral anticoagulation among heart failure patients with atrial fibrillation","volume":"163","author":"Suarez","year":"2012","journal-title":"Am Heart J"},{"key":"10.1016\/j.acvd.2014.01.001_bib0120","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1002\/pds.1471","article-title":"Guidelines for good pharmacoepidemiology practices (GPP)","volume":"17","year":"2008","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.acvd.2014.01.001_bib0125","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.acvd.2010.06.001","article-title":"Characteristics and management of outpatients with history of or current atrial fibrillation: the observational French EPHA study","volume":"103","author":"Cohen","year":"2010","journal-title":"Arch Cardiovasc Dis"},{"key":"10.1016\/j.acvd.2014.01.001_bib0130","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1093\/europace\/eun369","article-title":"The Registry of the German Competence NETwork on Atrial Fibrillation: patient characteristics and initial management","volume":"11","author":"Nabauer","year":"2009","journal-title":"Europace"},{"key":"10.1016\/j.acvd.2014.01.001_bib0135","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1093\/europace\/eut263","article-title":"Management of atrial fibrillation in seven European countries after the publication of the 2010 ESC Guidelines on atrial fibrillation: primary results of the PREvention oF thromboemolic events\u00a0\u2013\u00a0European Registry in Atrial Fibrillation (PREFER in AF)","volume":"16","author":"Kirchhof","year":"2014","journal-title":"Europace"},{"key":"10.1016\/j.acvd.2014.01.001_bib0140","doi-asserted-by":"crossref","first-page":"e63479","DOI":"10.1371\/journal.pone.0063479","article-title":"Risk profiles and antithrombotic treatment of patients newly diagnosed with atrial fibrillation at risk of stroke: perspectives from the international, observational, prospective GARFIELD registry","volume":"8","author":"Kakkar","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.acvd.2014.01.001_bib0145","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1161\/01.STR.0000194955.34820.78","article-title":"Incidence and trends of stroke and its subtypes in China: results from three large cities","volume":"37","author":"Jiang","year":"2006","journal-title":"Stroke"},{"key":"10.1016\/j.acvd.2014.01.001_bib0150","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1253\/circj.CJ-88-0001","article-title":"Guidelines for pharmacotherapy of atrial fibrillation (JCS 2008): digest version","volume":"74","year":"2010","journal-title":"Circ J"},{"key":"10.1016\/j.acvd.2014.01.001_bib0155","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1161\/01.STR.31.6.1217","article-title":"Warfarin for stroke prevention still underused in atrial fibrillation: patterns of omission","volume":"31","author":"Cohen","year":"2000","journal-title":"Stroke"},{"key":"10.1016\/j.acvd.2014.01.001_bib0160","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1253\/circj.68.417","article-title":"Attitudes of Japanese cardiologists toward anticoagulation for nonvalvular atrial fibrillation and reasons for its underuse","volume":"68","author":"Inoue","year":"2004","journal-title":"Circ J"},{"key":"10.1016\/j.acvd.2014.01.001_bib0165","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1001\/archinte.159.14.1574","article-title":"Temporal trends in the use of anticoagulants among older adults with atrial fibrillation","volume":"159","author":"Smith","year":"1999","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.acvd.2014.01.001_bib0170","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.amjmed.2005.09.052","article-title":"Warfarin prescribing in atrial fibrillation: the impact of physician, patient, and hospital characteristics","volume":"119","author":"Choudhry","year":"2006","journal-title":"Am J Med"},{"key":"10.1016\/j.acvd.2014.01.001_bib0175","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1536\/jhj.42.55","article-title":"Underutilization of anticoagulation therapy in chronic atrial fibrillation","volume":"42","author":"Guo","year":"2001","journal-title":"Jpn Heart J"},{"key":"10.1016\/j.acvd.2014.01.001_bib0180","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1471-2296-13-5","article-title":"Predictors of warfarin use in atrial fibrillation in the United States: a systematic review and meta-analysis","volume":"13","author":"Baczek","year":"2012","journal-title":"BMC Fam Pract"},{"key":"10.1016\/j.acvd.2014.01.001_bib0185","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1378\/chest.09-1584","article-title":"Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation","volume":"137","author":"Lip","year":"2010","journal-title":"Chest"},{"key":"10.1016\/j.acvd.2014.01.001_bib0190","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jacc.2010.09.024","volume":"57","author":"Lip","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.acvd.2014.01.001_bib0195","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1378\/chest.10-0134","article-title":"A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey","volume":"138","author":"Pisters","year":"2010","journal-title":"Chest"}],"container-title":["Archives of Cardiovascular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S187521361400014X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S187521361400014X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T13:41:06Z","timestamp":1761745266000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S187521361400014X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2]]},"references-count":39,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,2]]}},"alternative-id":["S187521361400014X"],"URL":"https:\/\/doi.org\/10.1016\/j.acvd.2014.01.001","relation":{},"ISSN":["1875-2136"],"issn-type":[{"value":"1875-2136","type":"print"}],"subject":[],"published":{"date-parts":[[2014,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Use of antithrombotics in atrial fibrillation in Africa, Europe, Asia and South America: Insights from the International RealiseAF Survey","name":"articletitle","label":"Article Title"},{"value":"Archives of Cardiovascular Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.acvd.2014.01.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}